Fuzuloparib and apatinib before surgery for ovarian cancer
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This trial tests a combination of two oral drugs—fuzuloparib (a PARP inhibitor) and apatinib (which blocks blood vessel growth to tumors)—given before surgery for advanced ovarian cancer that cannot be removed right away. It is for people whose tumors have a specific genetic marker (HRD positive) and who have not had prior cancer treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have newly diagnosed stage III or IV ovarian, fallopian tube, or primary peritoneal cancer that is high-grade or moderately/poorly differentiated.
- You are between 18 and 70 years old and in generally good health (able to do daily activities).
- A tumor sample or blood test shows you have a genetic change called HRD (homologous recombination deficiency).
- Surgery to remove the tumor is not possible at this time (either because the tumor is too widespread or your health doesn't allow it).
- You have not had prior treatment for ovarian cancer (including chemotherapy, PARP inhibitors, or certain anti-angiogenic drugs).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two drugs (fluzoparib with famitinib or SHR-1701) given before surgery to shrink advanced ovarian, fallopian tube, or primary peritoneal cancer. The goal is to see if these treatments can make tumors small enough for complete removal or improve the surgery outcome.
This trial tests whether combining fluzoparib (a PARP inhibitor) with or without bevacizumab (a blood vessel growth blocker) before surgery can shrink advanced ovarian cancer. It is for women with a BRCA gene mutation whose cancer cannot be fully removed with surgery right now.
This trial tests whether a combination of two drugs, fluzoparil and apatinib, can help keep ovarian cancer from coming back after platinum chemotherapy. It is for people whose cancer has either returned within 6 months (platinum-resistant) or after 6 months (platinum-sensitive) and who have responded to at least 4 more cycles of chemotherapy.
This trial checks whether having surgery to remove as much tumor as possible, followed by ongoing targeted treatment, helps people with advanced ovarian (and related) cancers live longer and/or control cancer better. It specifically uses tumor-testing results to match patients and then continues treatment after surgery.
This trial tests whether olaparib (a pill cancer medicine) works better than standard platinum chemotherapy after a second surgery for recurrent ovarian cancer. It’s for people whose cancer returned after initial PARP-inhibitor (PARPi) maintenance and aims to see if treatment can control the cancer for longer with acceptable side effects.
This trial tests if adding a drug called a PARP inhibitor (which helps block cancer cells from repairing themselves) to standard chemotherapy and heated chemotherapy during surgery (HIPEC) can work better together for ovarian cancer that has already been treated with initial chemo. It is for people with a specific type of advanced ovarian cancer who are planning surgery after chemo.
Hear when a new Ovarian cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.